3,890
+1.97%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SugenTech
Its shares trade on KOSDAQ under the ticker 253840.KQ. It has been listed since 11 November 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩9.42bn and a net loss of ₩23.31bn. At that date it held total assets of ₩98.21bn and shareholders' equity of ₩76.31bn.
Sugentech, Inc. develops in-vitro diagnostic systems and products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2016-11-11. The firm is involved in the manufacturing and sale of in vitro diagnostic test reagents, point-of-care testing (POCT) products, folic acid products under the name of SOLGAR, as well as molecular diagnostic reagents. The in vitro diagnostic test reagents are for personal use and are sold under the name SUREARLY. The POCT products are for professional use and are sold under the name INCLIX. In addition, the Company is engaged in therapeutic drug monitoring, as well as drug analysis method development. The firm distributes its products within the domestic market and to overseas markets, including Indonesia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 11 Nov 2016
- Website
- sugentech.com ↗
Leadership
Pay as last reported
- Ms. Mi Jin SonChief Executive Officer, Director₩2.10bn
- Mr. Hae Gwon LeeChief Financial Officer, Managing Director
- Mr. Seung Beom YooChief Technology Officer, Vice President, Director
- Ms. Su Jin GuManaging Director
- Ms. Eun Gyeong KimAssistant Managing Director
- Mr. Gang Min HuhNon-Executive Independent Director
- Mr. Jae Hong JeonNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sugentech develops in-vitro diagnostic systems and products for personal and professional use.
- Sugentech manufactures and sells in vitro diagnostic test reagents under SUREARLY and POCT products under INCLIX.
- Sugentech distributes products domestically and to overseas markets including Indonesia.
Weaknesses
- Sugentech's IPO was on 11 November 2016, which is a relatively recent listing.
- Sugentech is headquartered in Daejeon, a city that may not be a major global business hub.
- Sugentech's business is limited to Health Care sector with no diversification into other industries.
Opportunities
- Sugentech can expand its product line to include more molecular diagnostic reagents.
- Sugentech can target new overseas markets beyond Indonesia for its diagnostic products.
- Sugentech can leverage its therapeutic drug monitoring expertise for new partnerships.
Threats
- Sugentech faces competition from other Health Care companies in the in-vitro diagnostic market.
- Sugentech's reliance on the domestic market may limit its growth potential.
- Sugentech's products are subject to regulatory changes in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.